ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Approves Orencia in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Graft Versus Host Disease
December 17, 2021Bristol Myers Squibb announced that Orencia® (abatacept) was approved by the FDA for the prophylaxis, or prevention, of acute graft versus host disease (aGvHD), in combination with a calcineurin inhibitor (CNI) and methotrexate (MTX), in adults and...
Pharma Sources Insight January 2025
